Important Tax Note: Portfolia has delivered all K-1s before the March 15th deadline as we do every year. As always, these documents were sent through an encrypted email to protect your information from admin@moonstonecpa.com. For any questions or issues accessing your documents, please email members@portfolia.com.
Annual Fund Performance Report
EIN: 85-3330782
2025 Fund Performance Overview Session
The fund partners shared an overview of the fund's performance, current updates on all companies, and discussed how they're viewing the market.
2025 FemTech II Fund Performance Report
The 2025 financial statements are as of and for December 31, 2025. Please note all updates provided are confidential and not for distribution.
To access, use password:
2025FT2Report!
Semi-Annual Company Reports
The EOY highlights 2025 as provided by the companies are linked below. Please note all updates provided are confidential and not for distribution.
To access the file, use password: EOY25FT2!
FemTech II Portfolio Highlights
Portfolio Company Valuations
The Companies & Leadership Team
The Portfolia FemTech II Fund is led by a world-class team of highly sophisticated and experienced investors who are leaders in their respective fields, as venture capitalists, angel investors, and innovators. They bring an expert skill-set including sourcing, diligence, deal negotiation, executive recruitment, strategy and governance. Click on photos for full bios.
The Companies
xCures is a provider of a patient-centric AI-based virtual trial software intended to support advanced cancer patients and their doctors with evidence-based treatment options.
Developer of a subscription-based sexual wellness application intended to address sexual problems and questions.
A molecular diagnostics company at the intersection of epigenetics and AI tackling clinical problems where epigenetics appears to be involved such as infertility.
A digital clinic intended to provide women access to abortion pills. The company also offers services such as arranging consultations with licensed medical practioners, providing home delivery of prescribed medications, enabling women with an effective solution for at-home abortions, and increasing reproductive health equity.
Willow develops an in-bra wearable breast pump that is cordless and spill-proof. This also tracks milk output through a mobile app and online portal allowing for mothers to pump anywhere without hassle.
Attn Grace is a sustainable wellness brand designed for women, creating more sustainable solutions for women to combat bladder leakage.
A non-hormonal contraceptive designed to eliminate the risk of negative side effects associated with traditional hormonal contraceptives.
Nest Collaborative is a provider of on-demand lactation counseling services intended to offer international board-certified lactation consultants who conduct online video appointments, guiding moms through the breastfeeding process.
Offering at-home lab testing kits to make insightful testing and virtual care accessible to all, including its FDA-authorized Covid-19 Test Home Collection kit
A medical device company treating pulmonary arterial hypertension (PAH) by developing ways to enhance both the survival and quality of life of those with PAH.
Leveraging NASA research to develop a wearable medical device that is tackling an epidemic of low bone mass - osteopenia (moderate bone loss) and osteoporosis (severe bone loss).
Madorra has developed the first effective, non- hormonal treatment and new treatment paradigm for vaginal dryness.
Joylux is a health and wellness company that creates innovative, high-quality, safe, natural, and efficacious intimate health solutions that improve the quality of life in peri/post-menopausal women.
Portfolia Fund Partners
FemTech II & III, Women’s Health IV
Investment Lead: Attn: Grace, Hey Jane, Madison Reed
-Former CEO of Hello Products
-Former CMO of Godiva
-Former Head of Global Brands at Pfizer Consumer Healthcare.
-Advisory board member, Springboard Enterprises & The New York Fashion Tech Lab
FemTech I, II, & III, Women’s Health IV
CEO and Co-Founder of ExplORer Surgical
Vice President, Park Lane Ventures
Healthcare Associate, Hyde Park Angels
Consultant, Bain & Company
Kauffman Fellow
FemTech I, II, & III, Women’s Health IV
Investment Lead: Future Family, Maven Clinic, Joylux, Nest Collaborative
-Founding Member, Healthtech Capital
-Angel Capital Association Life Sciences Syndication Group Chair
-Advisor, One Health Group
FemTech II
-Medical Director, Maven Clinic
-Co-Founder, OB Best Practice
-Medical Advisor, Flex, Bobbie Baby
-Founding Member, Womxn’s Health Collaborative
FemTech I, Active Aging & Longevity, Medical Advisor FemTech II
-Founding CEO, One City Health Services
-Venture Partner, Phoenix Venture Seeds Fund
-Healthcare investor with deep experience integrating health tech
-Kauffman Fellow, NEA
FemTech I,II & III, Women’s Health IV
Investment Lead: Bone Health Technologies, Inherent Biosciences, xCures
-California Life Sciences Institute, Chair Emeritus
-Co-Founder and first CEO of Sequenom
-45+ years in the life sciences industry and in venture investments
Interested in other funds?
Connect with Investor Relations at investorrelations@portfolia.com
Additional questions?
Reach out to our team at members@portfolia.com